How can one determine whether a liver biopsy showing adenocarcinoma represents a primary hepatic tumor versus a metastatic deposit?

Determining Primary vs. Metastatic Adenocarcinoma in Liver Biopsy

Use a systematic immunohistochemical panel starting with CK7, CK20, and C-reactive protein (CRP), followed by site-specific markers (CDX2/SATB2, TTF1, GATA3) to differentiate primary intrahepatic cholangiocarcinoma from metastatic adenocarcinoma. 1

Initial Diagnostic Approach

The first critical step is obtaining both tumor tissue AND non-tumoral liver tissue during biopsy 1. The presence or absence of chronic liver disease, advanced fibrosis, or cirrhosis fundamentally changes your diagnostic algorithm—chronic liver disease strongly favors a primary hepatic malignancy.

Core Immunohistochemical Panel

First-Line Panel (Essential)

For suspected cholangiocarcinoma vs. metastasis:

• CK7 and CK20: The classic iCCA phenotype is CK7+ CK20− 1, 2
• CRP (C-reactive protein): Highly sensitive (76-93%) and specific (88-91%) for iCCA, particularly the small-duct subtype (97% sensitivity) 1
• CDX2 or SATB2: Negative in iCCA; positive indicates intestinal/gastric origin 1, 2
• TTF1: Negative in iCCA; positive indicates pulmonary origin 1, 2
• GATA3: Negative in iCCA; positive indicates breast origin (use in women) 1, 2

The diagnostic phenotype for intrahepatic cholangiocarcinoma is: CK7+ CK20− CRP+ with negative CDX2/SATB2, TTF1, and GATA3. 1

Site-Specific Patterns

When metastasis is suspected, recognize these patterns 2:

• Colon: CK7(−), CK20(+), CDX2/SATB2(+)
• Lung: CK7(+), CK20(−), TTF-1/napsin A(+)
• Breast: CK7(+), CK20(−), GATA3(+)
• Pancreas: CK7(+), CK19(+), CK20(−), N-cadherin(−)

Distinguishing from Hepatocellular Carcinoma

If the patient has chronic liver disease and you need to differentiate iCCA from HCC (not metastatic adenocarcinoma), add hepatocellular markers 1, 2:

• HepPar-1: 86-87% sensitive, 100% specific for HCC 3, 4
• Arginase-1: Highly specific for hepatocellular differentiation 1, 2
• Glypican-3: Specific for HCC 1
• CD10: Shows canalicular staining in 72-77% of HCC 3, 4
• pCEA: Canalicular pattern in 80% of HCC 4

Critical Pitfalls to Avoid

1. Don't rely on imaging alone: False-positive HCC diagnosis occurs in 11.4-63% of iCCA cases 2

2. Beware of atypical immunoprofiles: While rare, iCCA can be CK7− (<5%), CK19− (<10%), or even GATA3+ (5-10%) 1. Similarly, HCC can be CK7+/CK19+ (5-20%) depending on differentiation 1

3. Preserve tissue for molecular analysis: Don't exhaust your biopsy sample with excessive immunostaining 1. Molecular profiling may be needed for treatment decisions, particularly in high-risk cases 2

4. Consider hepatoid adenocarcinoma: This rare extrahepatic tumor mimics HCC morphologically and can metastasize to the liver, producing AFP 5. It requires exclusion of an extrahepatic primary (especially gastric)

When Doubt Persists

If immunohistochemistry remains inconclusive, pursue immunohistochemically-guided evaluations to identify an extrahepatic primary: 1

• Digestive endoscopy (for GI primaries)
• FDG-PET scanning
• Comprehensive imaging of chest, abdomen, and pelvis

The clinical context matters: absence of chronic liver disease shifts probability toward metastasis, while cirrhosis or chronic hepatitis B/C favors primary hepatic malignancy 1, 6.

Practical Algorithm Summary

1. Assess non-tumoral liver: Cirrhosis/fibrosis present? → Consider primary hepatic tumor
2. Apply basic panel: CK7, CK20, CRP
3. If CK7+ CK20−: Add CDX2/SATB2, TTF1, GATA3 to exclude metastases
4. If CK7+ CK20− CRP+ with negative site markers: Diagnosis is intrahepatic cholangiocarcinoma
5. If chronic liver disease present: Add HepPar-1, Arginase-1 to distinguish from HCC
6. If still uncertain: Pursue clinical workup for occult primary tumor